anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

189,961-190,020 of 319,975

filter-aware
93
The flywheel shows how retailer/OEM investment leads to more inventory, which attracts consumers, leading to more deals and conversion.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
94
Auto Trader Group | Investor Day Presentation Deck | 100 slidesAuto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
95
The slide uses a simple arithmetic equation structure (Price x Margin = Profit) to illustrate the value proposition.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
96
The slide uses a tabular structure to explain the decomposition of financial reporting segments.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
97
The diagram uses a concentric circle model to show how the three strategic pillars are layered and integrated.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
98
Auto Trader Group | Investor Day Presentation Deck | 100 slidesAuto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
99
Auto Trader Group | Investor Day Presentation Deck | 100 slidesAuto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
100
Auto Trader Group | Investor Day Presentation Deck | 100 slidesAuto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
01
Slide 1
Includes company logo and ticker symbol.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
02
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
03
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
04
The diagram illustrates a hub-and-spoke model showing systemic interaction of EMMs across various organs.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Propose Solution1 hit
05
The slide uses a calendar to imply a timeline or duration for Long COVID treatment.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
06
The slide uses a three-column structure to frame the problem: Market State, Biological Complexity, and Clinical Need.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Problem StatementLoop · Cost Of Inaction1 hit
07
The slide uses a timeline framework to show trial progression over time.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
08
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Key TakeawaysLoop · Cost Of Inaction1 hit
09
The slide uses a blue box with checkmarks to emphasize the positive attributes of the product.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
11
The slide uses a standard clinical trial flow diagram to illustrate study arms and assessment points.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
Standard clinical trial subject disposition flow chart.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The table includes demographic, metabolic, inflammatory, and fibrosis markers.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
15
The data shows a statistically significant improvement in the high-dose group at Week 24.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
16
The slide shows clinical trial data comparing two biomarkers for fibrosis treatment efficacy.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
17
Clinical trial data showing statistically significant reductions in ALT for AXA1125 groups compared to placebo.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Shows statistically significant effects at week 12 for AXA1125 treatment arms.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
Data shows proportions of subjects meeting specific thresholds associated with histologic improvements in NASH.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
20
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
21
DMC = Data Monitoring Committee; TEAE = Treatment Emergent Adverse Event; SAE = Serious Adverse Event.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
22
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
23
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
24
The slide uses a central biological pathway diagram (liver-centric) surrounded by comparative tables showing single-target drugs vs AXA1125's multi-target approach.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
25
The slide uses a central biological pathway map (liver/metabolic focus) flanked by comparison tables showing single-target competitors vs AXA1125's multi-target effects.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
26
The slide uses bar charts to show dose-dependent increases in metabolic markers and a table to show pathway enrichment scores.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
27
The slide uses a pathway diagram and a bar chart to demonstrate the mechanism of action of AXA1125 in a Primary Human Hepatocyte (PHH) Lipotoxicity Model.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
28
Includes statistical significance markers (*, **, ***) and experimental methodology in the footer.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
29
The slide presents preclinical data from primary human hepatic stellate cells.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
30
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
31
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
32
Includes a map-based visualization of regional prevalence and a grouped bar chart for age/sex demographics.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
33
Uses a before-after-bridge framework to highlight the growth in Fibrosis stage 2-4 prevalence.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
34
Data source: Harrison SA et al. J Hepatol. 2021;S0168-8278:00176-8.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses a background diagram of biological pathways to illustrate complexity, overlaid with a callout box containing the core thesis.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
36
Uses a gradient bar to illustrate the shift in risk tolerance and clinical priorities.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
37
The slide uses a table structure to categorize drug candidates by their biological mechanism of action.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
38
The slide outlines a clinical trial protocol for AXA1125.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
39
The slide includes a prominent callout box summarizing the clinical significance of the baseline data.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
40
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
41
The slide uses a simple three-circle layout to categorize the utility of NITs.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
42
The slide uses a simple Venn-like or hub-and-spoke visual, though the side circles are empty.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
43
The slide compares three groups (Placebo, AXA1125 22.6 BID, AXA1125 33.9 BID) across two time points (Week 12 and Week 24).Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
44
The chart compares different trial durations (24 weeks vs 72 weeks vs 18 months) and phases (Ph2b vs Ph3).Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
45
The slide title mentions week 12, but the charts explicitly label week 24. This is a common discrepancy in clinical trial decks where data is presented across multiple time points.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
46
N=931. Data presented for Placebo, OCA 10mg, and OCA 25mg cohorts.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
47
The slide presents longitudinal data from the REGENERATE trial, specifically focusing on FIB-4 scores as a non-invasive test (NIT) for fibrosis.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
48
P-values are calculated using Cochran-Mantel Haenszel test vs placebo.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
49
Figure 5 from a clinical study publication; includes legend for treatment arms.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
50
The slide uses a forest plot to visualize odds ratios and confidence intervals for clinical predictors.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
51
The slide uses a dark sidebar for context and a white main area for data presentation. It includes a citation at the bottom.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
52
The slide highlights the efficacy of MGL-3196 in NASH treatment using MRI-PDFF as a biomarker.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit